Long-term follow-up of HIV-infected patients
Official title: A Long-term Follow-up Study for HIV-infected Individuals Who Have Participated in HIV-NAT Study Protocols
Run by The HIV Netherlands Australia Thailand Research Collaboration · NCT00411983 · Data updated 2026-11-12
This study looks at how well different HIV treatments work and their long-term effects on the health and quality of life of people living with HIV.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 10000 (estimated) |
| Sponsor | The HIV Netherlands Australia Thailand Research Collaboration Academic / other |
| Locations | 1 site (Bangkok) |
| Status | Recruiting |
| Started | November 2002 |
| Main results expected | December 2030 |
| Study ends | December 2030 |
| Registry record updated | September 17, 2026 |
| Trial ID | NCT00411983 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include HIV-infected individuals, both children and adults, who have previously participated in HIV-NAT studies or are currently enrolled in HIV-NAT trials.
✕Probably not a fit
Patients who are unable to provide written consent will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to collect and evaluate long-term clinical outcomes of HIV-infected participants who were previously enrolled in HIV-NAT trials. It focuses on understanding the long-term safety and effectiveness of various antiretroviral therapies, assessing factors such as CD4 cell counts and HIV viral load as predictors of disease progression. The study will also investigate the incidence of metabolic complications, resistance profiles, and the overall quality of life among participants. By gathering extensive data over time, the study seeks to provide insights into the chronic management of HIV infection.
Why it matters
Potential benefit: If successful, this study could enhance our understanding of long-term HIV management and improve treatment strategies for patients.
How similar studies have gone: Other studies focusing on long-term outcomes in HIV management have shown promise, indicating that this approach is both relevant and necessary.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * HIV infected patients( children and adults) previously participated HIV-NAT studies * HIV infected patients( children and adults) currently participate in HIV-NAT trials * Able to provide written consent Exclusion Criteria: * Unable to provide written consent
Where it's running
-
HIV-NAT, Thai Red Cross AIDS Research Center
Bangkok, Thailand Recruiting
Study contacts
- Principal investigator: Praphan Phanuphak, MD, PhD — HIV-NAT, Thai Red Cross AIDS Research Center
- Study coordinator: Anchalee Avihingsanon, MD, PhD
- Email: anchalee.a@hivnat.org
- Phone: 66 2 2557334-5
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Camino HIV Prevention and Care Study
This study tests a combined legal and peer-support program to help Latin American adults in DC and the Bay Area improve HIV testing, PrEP use, and care engagement.
-
VH4367310 in healthy adults: testing single increasing doses for safety and how it behaves in the body
This study tests a single rising dose of VH4367310, a cabotegravir prodrug, to see how it behaves in the body and how safe and tolerable it is in healthy adults aged 18 to 55.
-
Online cohort of sexual and gender minorities testing digital support to boost PrEP and ART use
In Brazil, sexually and gender diverse adults are being followed online to see if weekly WhatsApp reminders help people stick to PrEP or ART.
-
Metabolic Liver Disease in People Newly Diagnosed with HIV
This study tests whether HIV-infected adults who are starting ART are more likely to develop MASLD and related liver issues than HIV-negative adults over five years.
-
Screen2Prevent: HIV screening for teens and young adults in emergency departments
The study tests three ways of offering HIV screening to people aged 14–24 in emergency departments to see if it helps link them to PrEP or HIV treatment using digital health tools.
-
Long-acting LEN/TAB/ZAB vs CAB/RPV in adults with HIV-1 who are virologically suppressed on daily ART
This study tests whether switching to a weekly-plus long-acting injectable regimen of lenacapavir, teropavimab, and zinlirvimab works as well as a two-drug injectable regimen of cabotegravir and rilpivirine for adults with HIV-1 who already have undetectable virus on daily treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.